Elizabeth Dudnik

2025

The impact of brain MRI screening on stage IV NSCLC patients: A real world look at guidelines based care

Waizman, E., Dudnik, E., Lavi, I., Rotem, O., Amiel, A., Siegal, T., Haim, S. E., Gal, O., Limon, D., Tschernichovsky, R., Kanner, A. A., Laviv, Y. & Katz, S. Y., 15 Mar 2025, In: Journal of the Neurological Sciences. 470, 123398.

Research output: Contribution to journal › Article › peer-review

2024

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

Illini, O., Saalfeld, F. C., Christopoulos, P., Duruisseaux, M., Vikström, A., Peled, N., Demedts, I., Dudnik, E., Eisert, A., Hashemi, S. M. S., Janzic, U., Kian, W., Mohorcic, K., Mohammed, S., Silvoniemi, M., Rothschild, S. I., Schulz, C., Wesseler, C., Addeo, A. & Armster, K. & 28 others, Itchins, M., Ivanović, M., Kauffmann-Guerrero, D., Koivunen, J., Kuon, J., Pavlakis, N., Piet, B., Sebastian, M., Velthaus-Rusik, J. L., Wannesson, L., Wiesweg, M., Wurm, R., Albers-Leischner, C., Aust, D. E., Janning, M., Fabikan, H., Herold, S., Klimova, A., Loges, S., Sharapova, Y., Schütz, M., Weinlinger, C., Valipour, A., Overbeck, T. R., Griesinger, F., Jakopovic, M., Hochmair, M. J. & Wermke, M., Apr 2024, In: International Journal of Molecular Sciences. 25, 7, 3992.

Research output: Contribution to journal › Article › peer-review

Open Access

2 Scopus citations

2023

<i>BRCA</i> mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course

Tschernichovsky, R., Averbuch, I., Goldstein, D. A., Mutai, R., Dudnik, E., Rotem, O., Laufer-Geva, S., Peled, N., Goldberg, Y. & Zer, A., May 2023, In: Translational Lung Cancer Research. 12, 5, p. 1011-1022 15 p.

Research output: Contribution to journal › Article › peer-review

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study

Icht, O., Leader, A., Batat, E., Yosef, L., Shochat, T., Goldstein, D. A., Dudnik, E., Spectre, G., Raanani, P., Hammerman, A. & Zer, A., Jun 2023, In: Oncologist. 28, 6, p. E391-E396

Research output: Contribution to journal › Article › peer-review

Open Access

5 Scopus citations

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy

Rotem, O., Zer, A., Yosef, L., Beery, E., Goldvaser, H., Gutkin, A., Levin, R., Dudnik, E., Berger, T., Feinmesser, M., Levy-Barda, A., Lahav, M., Raanani, P. & Uziel, O., Jun 2023, In: Biomedicines. 11, 6, 1730.

Research output: Contribution to journal › Article › peer-review

Open Access

2 Scopus citations

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature

Averbuch, I., Tschernichovsky, R., Icht, O., Goldstein, D. A., Mutai, R., Dudnik, E., Rotem, O., Peled, N., Allen, A. M., Laufer-Geva, S., Goldberg, Y. & Zer, A., Jun 2023, In: Thoracic Cancer. 14, 17, p. 1589-1596 8 p.

Research output: Contribution to journal › Article › peer-review

Open Access

3 Scopus citations

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study

Peled, N., Roisman, L. C., Levison, E., Dudnik, J., Chernomordikov, E., Heching, N., Dudnik, E., Keren-Rosenberg, S., Nechushtan, H., Salhab, A., Hershkovitz, D., Tsuriel, S., Hannes, V., Rotem, O., Lazarev, I., Lichtenberg, R., Granot, I. S., Krayim, B., Shalata, W. & Levin, D. & 5 others, Krutman, Y., Allen, A. M., Blumenfeld, P., Lavrenkov, K. & Kian, W., 1 Sep 2023, In: International Journal of Radiation Oncology Biology Physics. 117, 1, p. 105-114 10 p.

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

2022

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

On behalf of the Israel Lung Cancer Group (ILCG), Jan 2022, In: Oncologist. 27, 1, p. E76-E84

Research output: Contribution to journal › Article › peer-review

Open Access

4 Scopus citations

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

Holtzman, L., Moskovitz, M., Urban, D., Nechushtan, H., Keren, S., Reinhorn, D., Wollner, M., Daher, S., Rottenberg, Y., Rovitzky, Y., Shochat, T., Bar, J. & Dudnik, E., Mar 2022, In: Clinical Lung Cancer. 23, 2, p. 122-134 13 p.

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Raphael, A., Dudnik, E., Hershkovitz, D., Jain, S., Olsen, S., Soussan-Gutman, L., Ben-Shitrit, T., Dvir, A., Nechushtan, H., Peled, N., Onn, A. & Agbarya, A., 1 May 2022, In: Journal of Clinical Medicine. 11, 9, 2475.

Research output: Contribution to journal › Article › peer-review

Open Access

16 Scopus citations

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Peled, N., Kian, W., Inbar, E., Goldstein, I. M., Zemel, M., Rotem, O., Rozenblum, A. B., Nechushtan, H., Dudnik, E., Levin, D., Zer, A., Keren-Rosenberg, S., Yust-Katz, S., Fuchs, V., Remilah, A. A., Shelef, I. & Roisman, L. C., 1 Jan 2022, In: Neuro-Oncology Advances. 4, 1, vdab188.

Research output: Contribution to journal › Article › peer-review

Open Access

17 Scopus citations

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

Kian, W., Christopoulos, P., Remilah, A. A., Levison, E., Dudnik, E., Shalata, W., Krayim, B., Marei, R., Yakobson, A., Faehling, M., Kahala, D., Sara Granot, I., Levitas, D., Peled, N. & Roisman, L. C., 20 Sep 2022, In: Frontiers in Oncology. 12, 1010311.

Research output: Contribution to journal › Article › peer-review

Open Access

10 Scopus citations

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Illini, O., Fabikan, H., Swalduz, A., Vikström, A., Krenbek, D., Schumacher, M., Dudnik, E., Studnicka, M., Öhman, R., Wurm, R., Wannesson, L., Peled, N., Kian, W., Bar, J., Daher, S., Addeo, A., Rotem, O., Pall, G., Zer, A. & Saad, A. & 11 others, Cufer, T., Sorotsky, H. G., Hashemi, S. M. S., Mohorcic, K., Stoff, R., Rovitsky, Y., Keren-Rosenberg, S., Winder, T., Weinlinger, C., Valipour, A. & Hochmair, M. J., 2022, In: Therapeutic Advances in Medical Oncology. 14

Research output: Contribution to journal › Article › peer-review

Open Access

20 Scopus citations

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2^nd/3^rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

Raphael, A., Onn, A., Holtzman, L., Dudnik, J., Urban, D., Kian, W., Cohen, A. Y., Moskovitz, M., Zer, A., Bar, J., Rabinovich, N. M., Grynberg, S., Oedegaard, C., Agbarya, A., Peled, N., Shochat, T., Dudnik, E. & Israel Lung Cancer Group, L. C. G., 13 May 2022, In: Frontiers in Oncology. 12, 874712.

Research output: Contribution to journal › Article › peer-review

Open Access

2 Scopus citations

2021

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence

Israel Lung Cancer Group, 1 Mar 2021, In: International Journal of Cancer. 148, 5, p. 1183-1191 9 p.

Research output: Contribution to journal › Article › peer-review

Open Access

1 Scopus citations

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

the Israel Lung Cancer Group, 10 Mar 2021, In: Frontiers in Oncology. 11, 603223.

Research output: Contribution to journal › Article › peer-review

Open Access

12 Scopus citations

Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors

Moore, A., Yust-Katz, S., Icht, O., Eliyahou, R., Gordon, N., Cohen, A. Y., Goldstein, I. M., Peled, N., Seigal, T., Amiel, A. & Dudnik, E., 15 Aug 2021, In: Journal of the Neurological Sciences. 427, 117556.

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

Landman, Y., Jacobi, O., Kurman, N., Yariv, O., Peretz, I., Rotem, O., Dudnik, E., Zer, A. & Allen, A. M., 2021, In: OncoImmunology. 10, 1, 1959979.

Research output: Contribution to journal › Article › peer-review

Open Access

33 Scopus citations

Height in adolescence as a risk factor for glioma subtypes: A nationwide retrospective cohort study of 2.2 million subjects

Tschernichovsky, R., Katz, L. H., Derazne, E., Berliner, M. B. Z., Simchoni, M., Levine, H., Keinan-Boker, L., Benouaich-Amiel, A., Kanner, A. A., Laviv, Y., Honig, A., Dudnik, E., Siegal, T., Mandel, J., Twig, G. & Yust-Katz, S., 1 Aug 2021, In: Neuro-Oncology. 23, 8, p. 1383-1392 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

3 Scopus citations

Long term follow-up of EGFR mutated NSCLC cases

Rennert, G., Gottfried, M., Rennert, H. S., Lejbkowicz, F., Frank, M., Cohen, I., Kelt, S., Agbarya, A., Dudnik, E., Dudnik, J., Katznelson, R., Mishali, M., Maimon Rabinovich, N., Nechushtan, H., Onn, A., Keren Rosenberg, S., Wollner, M., Zer, A., Bar, J. & Gronich, N., Jan 2021, In: Translational Oncology. 14, 1, 100934.

Research output: Contribution to journal › Article › peer-review

Open Access

9 Scopus citations

Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer

Icht, O., Domachevsky, L., Groshar, D., Dudnik, E., Rotem, O., Allen, A. M., Peled, N., Reinhorn, D., Jacobi, O., Shochat, T., Bernstine, H. & Zer, A., Apr 2021, In: Asia-Pacific Journal of Clinical Oncology. 17, 2, p. e125-e131

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Multicentric non-enhancing lesions in glioblastoma: A retrospective study

Benouaich-Amiel, A., Khasminsky, V., Gal, O., Weiss, T., Fichman, S., Kanner, A. A., Berkowitz, S., Laviv, Y., Mandel, J., Dudnik, E., Siegal, T. & Yust-Katz, S., Mar 2021, In: Journal of Clinical Neuroscience. 85, p. 20-26 7 p.

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Next-generation sequencing in thyroid cancers: Do targetable alterations lead to a therapeutic advantage?: A multicenter experience

Moore, A., Bar, Y., Maurice-Dror, C., Finkel, I., Goldvaser, H., Dudnik, E., Goldstein, D. A., Gordon, N., Billan, S., Gutfeld, O., Wolf, I. & Popovtzer, A., 25 Jun 2021, In: Medicine (United States). 100, 25, p. E26388

Research output: Contribution to journal › Article › peer-review

Open Access

9 Scopus citations

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

the Israel Lung Cancer Group, 21 Jul 2021, In: Frontiers in Oncology. 11, 625668.

Research output: Contribution to journal › Article › peer-review

Open Access

11 Scopus citations

Novel and Promising Systemic Treatment Approaches in Mesothelioma

Dudnik, E., Reinhorn, D. & Holtzman, L., Oct 2021, In: Current Treatment Options in Oncology. 22, 10, 89.

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

On behalf of the Israel Lung Cancer Group, 2021, In: OncoImmunology. 10, 1, 1865653.

Research output: Contribution to journal › Article › peer-review

Open Access

35 Scopus citations

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

Dudnik, E., Kareff, S., Moskovitz, M., Kim, C., Liu, S. V., Lobachov, A., Gottfried, T., Urban, D., Zer, A., Rotem, O., Onn, A., Wollner, M. & Bar, J., 17 Feb 2021, In: Journal for ImmunoTherapy of Cancer. 9, 2, e001999.

Research output: Contribution to journal › Article › peer-review

Open Access

35 Scopus citations

Rising incidence of lung cancer in Arab females, Jewish females, and Arab males from 1990 to 2014 in Israel

Israel Lung Cancer Group, 2021, In: Israel Medical Association Journal. 22, 12, p. 788-793 6 p.

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

Jacobi, O., Landman, Y., Reinhorn, D., Icht, O., Sternschuss, M., Rotem, O., Finkel, I., Allen, A. M., Dudnik, E., Goldstein, D. A. & Zer, A., 1 Aug 2021, In: Oncology. 99, 9, p. 555-561 7 p.

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)

Addeo, A., Hochmair, M., Janzic, U., Dudnik, E., Charpidou, A., Płużanński, A., Ciuleanu, T., Donev, I. S., Elbaz, J., Aarøe, J., Ott, R. & Peled, N., Nov 2021, In: Therapeutic Advances in Medical Oncology. 13

Research output: Contribution to journal › Article › peer-review

Open Access

6 Scopus citations

Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors

Icht, O., Darzi, N., Shimony, S., Jacobi, O., Reinhorn, D., Landman, Y., Mutai, R., Averbuch, I., Shochat, T., Spectre, G., Raanani, P., Rotem, O., Dudnik, E., Peled, N., Zer, A. & Leader, A., May 2021, In: Journal of Thrombosis and Haemostasis. 19, 5, p. 1250-1258 9 p.

Research output: Contribution to journal › Article › peer-review

Open Access

47 Scopus citations

2020

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?

Sternschuss, M., Peled, N., Allen, A. M., Dudnik, E., Rotem, O., Kurman, N., Gal, O., Reches, H. & Zer, A., 1 Aug 2020, In: Thoracic Cancer. 11, 8, p. 2331-2334 4 p.

Research output: Contribution to journal › Article › peer-review

Open Access

8 Scopus citations

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

the Israel Lung Cancer Group, 1 Dec 2020, In: Clinical and Translational Oncology. 22, 12, p. 2303-2311 9 p.

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Sherman, S., Rotem, O., Shochat, T., Zer, A., Moore, A. & Dudnik, E., May 2020, In: Lung Cancer. 143, p. 40-46 7 p.

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled, N., Gillis, R., Kilickap, S., Froesch, P., Orlov, S., Filippova, E., Demirci, U., Christopoulos, P., Cicin, I., Basal, F. B., Yilmaz, C., Fedor, M., Korkmaz, T., Paydas, S., Gautschi, O., Zirtiloglu, A., Eralp, Y., Cinkir, H. Y., Sezer, A. & Erman, M. & 28 others, Tural, D., Turna, H., Mazieres, J., Dudnik, E., Reguart, N., Camidge, D. R., Ng, T. L., Şenler, F. Ç., Beypınar, İ., Yazılıtaş, D., Demirkazık, A., Karaoğlu, A., Okutur, K., Coşkun, H. Ş., Şendur, M. A. N., Isikdogan, A., Cabuk, D., Yumuk, P. F., Yıldız, I., Kaplan, M. A., Özyılkan, Ö., Öztop, İ., Olmez, O. F., Aydin, K., Aydıner, A., Meydan, N., Grinberg, R. D. & Roisman, L. C., Oct 2020, In: Lung Cancer. 148, p. 48-54 7 p.

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Immune-related Neutropenia Following Treatment with Immune Checkpoint Inhibitors

Israel Lung Cancer Group, 1 Feb 2020, In: Journal of Immunotherapy. 43, 2, p. 67-74 8 p.

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Lung Cancer in Israel

Grinberg, R. D., Refaely, Y., Cohen, L. B., Shaham, D., Dudnik, E., Pfeffer, R., Allen, A. & Peled, N., Apr 2020, In: Journal of Thoracic Oncology. 15, 4, p. 493-498 6 p.

Research output: Contribution to journal › Editorial

Open Access

2 Scopus citations

Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant

Moore, A., Kramer, M. R., Rosengarten, D., Shtraichman, O., Zer, A., Dudnik, E., Korzets, Y. & Allen, A. M., 17 Apr 2020, In: Radiology and Oncology. 54, 2, p. 227-232 6 p.

Research output: Contribution to journal › Article › peer-review

Open Access

1 Scopus citations

Stereotactic radiosurgery for brain metastases in small cell lung cancer: The Davidoff Cancer Center experience

Dudnik, E., Allen, A. M., Michaeli, N., Benouaich-Amiel, A., Shochat, T., Peled, N., Finkel, I., Zer, A., Rotem, O. & Yust-Katz, S., 2020, In: Israel Medical Association Journal. 22, 1, p. 22-26 5 p.

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer

Reinhorn, D., Jacobi, O., Icht, O., Dudnik, E., Rotem, O., Zer, A. & Goldstein, D. A., Mar 2020, In: Immunotherapy. 12, 4, p. 235-243 9 p.

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Gal, O., Dudnik, E., Rotem, O., Finkel, I., Peretz, I., Zer, A., Mandel, J., Amiel, A., Siegal, T., Bar, J., Lobachov, A. & Yust, S., 2020, In: Journal of Oncology. 2020, 1980891.

Research output: Contribution to journal › Article › peer-review

Open Access

3 Scopus citations

2019

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

Bar, J., Markel, G., Gottfried, T., Percik, R., Leibowitz-Amit, R., Berger, R., Golan, T., Daher, S., Taliansky, A., Dudnik, E., Shulman, K., Urban, D. & Onn, A., Oct 2019, In: European Journal of Cancer. 120, p. 122-131 10 p.

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Circulating tumor DNA T790M testing as a predictor of osimertinib efficacy in epidermal growth factor receptor mutant non-small cell lung cancer: A single center experience

Makarov, M., Peled, N., Shochat, T., Zer, M., Rotem, O. & Dudnik, E., Jun 2019, In: Israel Medical Association Journal. 21, 6, p. 394-398 5 p.

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK -Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort

Bedas, A., Peled, N., Maimon Rabinovich, N., Mishaeli, M., Shochat, T., Zer, A., Rotem, O., Allen, A. M., Bar, J. & Dudnik, E., 1 May 2019, In: Oncology Research and Treatment. 42, 5, p. 275-282 8 p.

Research output: Contribution to journal › Article › peer-review

Open Access

14 Scopus citations

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non–Small-Cell Lung Cancer: Findings From a Real-Life Cohort

Israel Lung Cancer Group, Jul 2019, In: Clinical Lung Cancer. 20, 4, p. 278-286.e1

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Lung cancer in young patients: Higher rate of driver mutations and brain involvement, but better survival

Suidan, A. M., Roisman, L., Rozenblum, A. B., Ilouze, M., Dudnik, E., Zer, A. & Peled, N., 2019, In: Journal of global oncology. 2019, 5, p. 1-8 8 p.

Research output: Contribution to journal › Article › peer-review

Open Access

41 Scopus citations

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

Ratzon, R., Tamir, S., Friehmann, T., Livneh, N., Dudnik, E., Rozental, A., Hamburger-Avnery, O., Pereg, D., Derazne, E., Brenner, B., Raanani, P., ten Cate, H., Spectre, G. & Leader, A., 15 Jan 2019, In: Journal of Thrombosis and Thrombolysis. 47, 1, p. 121-128 8 p.

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

2018

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience

Purim, O., Beny, A., Inbar, M., Shulman, K., Brenner, B., Dudnik, E., Bokstein, F., Temper, M., Limon, D., Matceyevsky, D., Sarid, D., Segal, A., Semenisty, V., Brenner, R., Peretz, T., Idelevich, E., Pelles-Avraham, S., Meirovitz, A., Figer, A. & Russell, K. & 4 others, Voss, A., Dvir, A., Soussan-Gutman, L. & Hubert, A., 1 Apr 2018, In: Targeted Oncology. 13, 2, p. 217-226 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

8 Scopus citations

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Israel Lung Cancer Group, Aug 2018, In: Journal of Thoracic Oncology. 13, 8, p. 1128-1137 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

193 Scopus citations

Circulating cell-free tumor DNA in the management of double primary tumors

Dudnik, E., Twito, T., Faull, I., Dvir, A., Soussan-Gutman, L., Purim, O. & Lanman, R. B., 2018, In: JCO Precision Oncology. 2, p. 1-6 6 p.

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Elizabeth Dudnik

Research output

Search results